1. Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer;Rigas;J Clin Oncol,2003
2. The proteasome: a suitable antineoplastic target;Adams;Nat Rev Cancer,2004
3. The proteasome inhibitor PS-341 (bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (E-SCLC): a SWOG (0327) phase II trial;Johl;J Clin Oncl,2005
4. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition;Cusack;Cancer Res,2001
5. Quantitative distribution of cluster 1 small cell lung cancer antigen in cancerous and non-cancerous tissues, cultured cells and sera;Hirano;Jpn J Cancer Res,1989